Wells Fargo keeps Pharvaris at Overweight; price target raised
Wells Fargo maintained Pharvaris at Overweight and raised its price target to $65.00 per share from $55.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.